ArriVent BioPharma, Inc. Common Stock AVBP
i
Market dataready · fetched 2026-11-11T14:39:37.446Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:39:34.851728478Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T14:39:37.099813+00:00
ArriVent BioPharma, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 10.60 | 209.0% | 25.3% | |||
| 25Δ | 11.27 | 196.3% | 21.4% | |||
| 30Δ | 11.93 | 183.5% | 17.5% | |||
| 35Δ | 12.57 | 172.9% | 14.0% | |||
| 40Δ | 13.08 | 175.9% | 12.6% | |||
| 45Δ | 13.58 | 178.8% | 11.2% | |||
| 50Δ | 14.32 | 237.8% | 19.1% | 14.09 | 181.8% | 9.8% |
| 55Δ | 13.71 | 252.7% | 17.3% | 14.60 | 184.7% | 8.4% |
| 60Δ | 13.11 | 267.5% | 15.5% | 15.09 | 185.0% | 7.1% |
| 65Δ | 12.50 | 282.4% | 13.7% | 15.52 | 175.1% | 6.0% |
| 70Δ | 12.02 | 257.6% | 11.3% | 15.95 | 165.1% | 4.9% |
| 75Δ | 11.53 | 232.8% | 8.9% | 16.38 | 155.2% | 3.8% |
| 80Δ | 11.04 | 208.0% | 6.5% | 16.81 | 145.3% | 2.7% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.60
- IV
- 209.0%
- B/E move
- 25.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.27
- IV
- 196.3%
- B/E move
- 21.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.93
- IV
- 183.5%
- B/E move
- 17.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.57
- IV
- 172.9%
- B/E move
- 14.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.08
- IV
- 175.9%
- B/E move
- 12.6%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.58
- IV
- 178.8%
- B/E move
- 11.2%
50Δ
- Pseudo strike
- 14.32
- IV
- 237.8%
- B/E move
- 19.1%
- Pseudo strike
- 14.09
- IV
- 181.8%
- B/E move
- 9.8%
55Δ
- Pseudo strike
- 13.71
- IV
- 252.7%
- B/E move
- 17.3%
- Pseudo strike
- 14.60
- IV
- 184.7%
- B/E move
- 8.4%
60Δ
- Pseudo strike
- 13.11
- IV
- 267.5%
- B/E move
- 15.5%
- Pseudo strike
- 15.09
- IV
- 185.0%
- B/E move
- 7.1%
65Δ
- Pseudo strike
- 12.50
- IV
- 282.4%
- B/E move
- 13.7%
- Pseudo strike
- 15.52
- IV
- 175.1%
- B/E move
- 6.0%
70Δ
- Pseudo strike
- 12.02
- IV
- 257.6%
- B/E move
- 11.3%
- Pseudo strike
- 15.95
- IV
- 165.1%
- B/E move
- 4.9%
75Δ
- Pseudo strike
- 11.53
- IV
- 232.8%
- B/E move
- 8.9%
- Pseudo strike
- 16.38
- IV
- 155.2%
- B/E move
- 3.8%
80Δ
- Pseudo strike
- 11.04
- IV
- 208.0%
- B/E move
- 6.5%
- Pseudo strike
- 16.81
- IV
- 145.3%
- B/E move
- 2.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 99.30% | |
| 98.31% | |
| 95.23% | |
| 101.19% | |
| 105.19% | |
| 111.75% | |
| 115.33% | |
| 105.13% | |
| 115.35% | |
| 122.82% |
Biotechnology
AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral…
More →AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe respiratory diseases, with its lead candidate, AV-101,…
More →AVTX
Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly…
More →AVXL
Anavex Life Sciences Corp. The company is headquartered in New York, New York.
More →AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is…
More →BBIO
Description unavailable
More →